• Renu Sharma Department of Biotechnology, Molecular Neuroscience and Functional Genomics Laboratory, Delhi Technological University (Formerly DCE), New Delhi, India.
  • Pravir Kumar Department of Biotechnology, Molecular Neuroscience and Functional Genomics Laboratory, Delhi Technological University (Formerly DCE), New Delhi, India



Nil, Bimoclomol, Cell cycle, Heat shock proteins 70, Therapeutics


Objective: Parkinson's disease (PD) is a debilitating age-related neurodegenerative disease characterized by the canonical formation of intracellular Lewy bodies comprising α-synuclein protein. Despite the knowledge of factors causing PD, it remains irreversible and incurable. Recent studies have highlighted the physiological and pathological involvement of cell cycle proteins in PD. The intriguing relationship between PARK2 and cyclin E which leads to upregulation of cyclin E in the absence of functional PARK2 contributes heavily in the onset and progression of PD. The objective of this study is to explore neuroprotective action of bimoclomol in attenuating the level of cyclin E and inhibiting post-mitotic cell division led neurodegeneration in PD.

Methods: We employed various in silico methods such as drug-likeness parameters, namely, Lipinski filter analysis, Ghose parameters, Veber rules, absorption, distribution, metabolism, and excretion - toxicity analysis, pharmacophore based target prediction, active site prediction, and molecular docking studies.

Results: The binding of bimoclomol inhibited cyclin E, thereby, attenuating post-mitotic cell division led neurodegeneration in PD.

Conclusion: This study outlines the novel potential of bimoclomol in attenuating cyclin E led neuronal death in PD which may be mediated by heat shock proteins (HSP70).


Download data is not yet available.

Author Biographies

Renu Sharma, Department of Biotechnology, Molecular Neuroscience and Functional Genomics Laboratory, Delhi Technological University (Formerly DCE), New Delhi, India.

PhD student of Dr Pravir Kumar

Pravir Kumar, Department of Biotechnology, Molecular Neuroscience and Functional Genomics Laboratory, Delhi Technological University (Formerly DCE), New Delhi, India

Associate Professor at Delhi Technological University (Former Delhi College of Engineering);

Ex-Faculty, Neurology Depaertment, Tufts University School of Medicine, Boston, MA USA


Ebrahimi-Fakhari D, Wahlster L, McLean PJ. Molecular chaperones in Parkinson’s disease - Present and future. J Parkinsons Dis 2011;1(4):299-320.

Sharma R, Kumar D, Jha NK, Jha SK, Ambasta RK, Kumar P. Re-expression of cell cycle markers in aged neurons and muscles: Whether cells should divide or die? Biochim Biophys Acta 2017;1863(1):324-36.

O’Flanagan CH, Morais VA, Wurst W, De Strooper B, O’Neill C. The Parkinson’s gene PINK1 regulates cell cycle progression and promotes cancer-associated phenotypes. Oncogene 2015;34(11):1363-74.

Camins A, Pizarro JG, Alvira D, Gutierrez-Cuesta J, de la Torre AV, Folch J, et al. Activation of ataxia telangiectasia muted under experimental models and human Parkinson’s disease. Cell Mol Life Sci2010;67(22):3865-82.

Feng DD, Cai W, Chen X. The associations between Parkinson’s disease and cancer: The plot thickens. Transl Neurodegener 2015;4:20.

Kwon B, Kumar P, Lee HK, Zeng L, Walsh K, Fu Q, et al. Aberrant cell cycle reentry in human and experimental inclusion body myositis and polymyositis. Hum Mol Genet 2014;23(14):3681-94.

Keppel Hesselink JM. Bimoclomol and arimoclomol: HSP-co-inducers for the treatment of protein misfolding disorders, neuropathy and neuropathic pain. J Pain Relief 2016;6:279.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46(1-3):3-26.

Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1999;1(1):55-68.

Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45(12):2615-23.

Liu X, Ouyang S, Yu B, Liu Y, Huang K, Gong J, et al. PharmMapper server: A web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res 2010;38:W609-14.

Hussein HA, Borrel A, Geneix C, Petitjean M, Regad L, Camproux AC. PockDrug-server: A new web server for predicting pocket druggability on holo and apo proteins. Nucleic Acids Res 2015;43:W436-42.

Bikadi Z, Hazai E. Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock. J Cheminform 2009;1:15.

Morris GM, Goodsell DS. Automated docking using a genetic lamarckian algorithm and an empirical binding free energy function. J Comput Chem 1998;19(14):1639-62.

Soils FJ, Wets RJ. Minimization by random search techniques. Math Oper Res 1981;6(1):19-30.

Xia C, Cai Y, Li S, Yang J, Xiao G. Curcumin increases HSP70 expression in primary rat cortical neuronal apoptosis induced by gp120 V3 loop peptide. Neurochem Res 2015;40:1996-2005.

Sharma S, Kumar V. In vitro cytotoxicity effect on mcf-7 cell line of co-encapsulated artesunate and curcumin liposome. Int J Pharm Pharm Sci 2017;9(3):123-8.

Joshi H, Bhandari U, Panda BP. To assess the potential of curcumin against gut microbiota-induced alteration in choline metabolism in c57bl/6j mice. Int J Pharm Pharm Sci 2017;9(3):215-26.

Deane CA, Brown IR. Induction of heat shock proteins in differentiated human neuronal cells following co-application of celastrol and arimoclomol. Cell Stress Chaperones 2016;21(5):837-48.

Khadka P, Jieun R, Kim H, Kim I, Kim JT, Kim H, et al. Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability. Asian J Pharm Sci 2014;9(6):304-16.

Chico LK, Van Eldik LJ, Watterson DM. Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov 2009;8(11):892-909.

Wager TT, Hou X, Verhoest PR, Villalobos A. Moving beyond rules: The development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci 2010;1(6):435-49.



How to Cite

Sharma, R., and P. Kumar. “NEUROPROTECTIVE ROLE OF BIMOCLOMOL IN ECTOPIC CELL CYCLE IN PARKINSON’S DISEASE: NEW INSIGHTS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 10, no. 6, June 2017, pp. 180-3, doi:10.22159/ajpcr.2017.v10i6.17971.



Original Article(s)